CAMP/ 06/10/2026 · 11:40 AM Chardan Slaps “Buy” Rating on CAMP4 Therapeutics – $6.50 Price Target Signals 60%+ Upside Its new gene-boosting drug shows promise for rare brain disorders with no treatments yet.
